Condition: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms · Sponsor: Axsome Therapeutics, Inc.
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.
This description comes directly from the study's public registry record.
Study Director · 2123325061 · sol-mdd-302@axsome.com
Always discuss trial participation with your own doctor first.
| Clinical Research Site | Tucson, Arizona, United States | Recruiting |
| Clinical Research Site | Bellflower, California, United States | Recruiting |
| Clinical Research Site | Chino, California, United States | Recruiting |
| Clinical Research Site | Glendale, California, United States | Recruiting |
| Clinical Research Site | Imperial, California, United States | Recruiting |
| Clinical Research Site | Los Angeles, California, United States | Recruiting |
| Clinical Research Site | Oceanside, California, United States | Recruiting |
| Clinical Research Site | Redlands, California, United States | Recruiting |
| Clinical Research Site | San Diego, California, United States | Recruiting |
| Clinical Research Site | Sherman Oaks, California, United States | Recruiting |
| Clinical Research Site | Walnut Creek, California, United States | Recruiting |
| Clinical Research Site | Jacksonville, Florida, United States | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07484217